Wire · opportunities
US FDA approves Replimune's skin cancer drug after prior rejections
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The US FDA has approved Replimune's drug Tudriqev, a genetically modified herpes virus treatment combined with Bristol Myers Squibb's Opdivo for advanced melanoma patients whose tumors progressed despite previous treatments. This approval follows previous rejections and is based on clinical data showing tumour reduction, with confirmatory trials ongoing.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 6 Aug 2026 and 10 Aug 2026.
◆ ◆ The Wire takeaway
You face a loosening of FDA standards for melanoma treatments after Replimune’s approval with limited prior evidence, opening a route to market faster but with ongoing proof needed. Plan your regulatory strategy around approvals that use confirmatory studies post-launch, not just upfront data.
◆ Coverage
14 sources · first reported 6 Aug 2026 · latest 10 Aug 2026
◆ Related on Wire
◆ Topics